Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.

Fusion Pharmaceuticals, a Canada-based cancer treatment spinout of McMaster University, has closed a $105m series B round led by oncology technology provider Varian Medical Systems. Fight Against Cancer Innovation Trust (Facit), a commercialisation unit backed by Ontario Institute for Cancer Research and the province of Ontario, participated in the round, as did medical group Johnson…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.